<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="phy270335" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Physiol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Physiol Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2051-817X</journal-id><journal-id journal-id-type="publisher-id">PHY2</journal-id><journal-id journal-id-type="hwp">physreports</journal-id><journal-title-group><journal-title>Physiological Reports</journal-title></journal-title-group><issn pub-type="epub">2051-817X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405523</article-id><article-id pub-id-type="pmc">PMC12098967</article-id><article-id pub-id-type="doi">10.14814/phy2.70335</article-id><article-id pub-id-type="publisher-id">PHY270335</article-id><article-id pub-id-type="other">PHYSREP-2025-02-093-T</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice</article-title><alt-title alt-title-type="left-running-head">Maakoul et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="phy270335-cr-0001" contrib-type="author"><name><surname>Maakoul</surname><given-names>Zakaria</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="phy270335-cr-0002" contrib-type="author"><name><surname>Yegen</surname><given-names>Celine&#x02010;Hivda</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="phy270335-cr-0003" contrib-type="author"><name><surname>Marchant</surname><given-names>Dominique</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="phy270335-cr-0004" contrib-type="author"><name><surname>Bernaudin</surname><given-names>Jean&#x02010;Francois</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="phy270335-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="phy270335-cr-0005" contrib-type="author"><name><surname>Plan&#x000e8;s</surname><given-names>Carole</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="phy270335-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="phy270335-cr-0006" contrib-type="author" corresp="yes"><name><surname>Voituron</surname><given-names>Nicolas</given-names></name><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>nicolas.voituron@univ-paris13.fr</email></address></contrib><contrib id="phy270335-cr-0007" contrib-type="author" corresp="yes"><name><surname>Boncoeur</surname><given-names>Emilie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1719-9808</contrib-id><xref rid="phy270335-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="phy270335-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>emilie.boncoeur@inserm.fr</email></address></contrib></contrib-group><aff id="phy270335-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laboratoire Hypoxie &#x00026; Poumon, UMR INSERM U1272</named-content>
<institution>Universit&#x000e9; Sorbonne Paris&#x02010;Nord</institution>
<city>Bobigny</city>
<country country="FR">France</country>
</aff><aff id="phy270335-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Facult&#x000e9; de M&#x000e9;decine</named-content>
<institution>Sorbonne Universit&#x000e9;</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="phy270335-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Service de Physiologie et d'Explorations Fonctionnelles</named-content>
<institution>H&#x000f4;pital Avicenne, APHP</institution>
<city>Bobigny</city>
<country country="FR">France</country>
</aff><aff id="phy270335-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Univ. Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, FR2048 ProFI</named-content>
<institution>EDyP Team</institution>
<city>Grenoble</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Emilie Boncoeur and Nicolas Voituron, Laboratoire Hypoxie &#x00026; Poumon, UMR INSERM U1272, Universit&#x000e9; Sorbonne Paris&#x02010;Nord, 93000 Bobigny, France.<break/>
Email: <email>emilie.boncoeur@inserm.fr</email> and <email>nicolas.voituron@univ-paris13.fr</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>13</volume><issue seq="260">10</issue><issue-id pub-id-type="doi">10.14814/phy2.v13.10</issue-id><elocation-id>e70335</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>06</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Published by the Physiological Society and the American Physiological Society--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Physiological Reports</italic> published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PHY2-13-e70335.pdf"/><abstract><title>Abstract</title><p>Obstructive sleep apnoea (<styled-content style="fixed-case" toggle="no">OSA</styled-content>) leading to chronic intermittent hypoxia (<styled-content style="fixed-case" toggle="no">CIH</styled-content>) is a common comorbidity associated with idiopathic pulmonary fibrosis (<styled-content style="fixed-case" toggle="no">IPF</styled-content>), a progressive fatal disease characterized by adverse lung remodeling and parenchymal stiffening. In the mouse model of lung fibrosis induced by intra&#x02010;tracheal instillation (<styled-content style="fixed-case" toggle="no">ITI</styled-content>) of bleomycin, we have previously shown that <styled-content style="fixed-case" toggle="no">CIH</styled-content> exacerbates fibrosis, similar to pre&#x02010;exposure to <styled-content style="fixed-case" toggle="no">ITI</styled-content>. It has been suggested that correction of <styled-content style="fixed-case" toggle="no">OSA</styled-content> and <styled-content style="fixed-case" toggle="no">CIH</styled-content> with positive airway pressure may have a beneficial effect on the progression of fibrosis in <styled-content style="fixed-case" toggle="no">IPF</styled-content> patients. Therefore, we designed this study to determine the benefits of stopping <styled-content style="fixed-case" toggle="no">CIH</styled-content> in mice pre&#x02010;exposed to <styled-content style="fixed-case" toggle="no">CIH</styled-content> for 3&#x02009;weeks prior to bleomycin <styled-content style="fixed-case" toggle="no">ITI</styled-content>. Interruption of <styled-content style="fixed-case" toggle="no">CIH</styled-content> exposure was associated with less diffuse lung fibrosis, reduced ratio of damaged area, alveolar destruction, collagen deposition, and fibrosis score. Interruption of <styled-content style="fixed-case" toggle="no">CIH</styled-content> exposure significantly reduced macrophage density in fibrotic areas without significant changes in either lymphocyte or neutrophil density. In conclusion, this study demonstrates that early treatment of <styled-content style="fixed-case" toggle="no">OSA</styled-content>&#x02010;associated <styled-content style="fixed-case" toggle="no">CIH</styled-content> can limit or reduce the development of severe forms of pulmonary fibrosis associated with a reduction in macrophage infiltrate and supports the beneficial effect of <styled-content style="fixed-case" toggle="no">CIH</styled-content> exposure interruption on ongoing fibrosis severity.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="phy270335-kwd-0001">intermittent hypoxia</kwd><kwd id="phy270335-kwd-0002">lung damages</kwd><kwd id="phy270335-kwd-0003">macrophages</kwd><kwd id="phy270335-kwd-0004">obstructive sleep apnoea</kwd><kwd id="phy270335-kwd-0005">pulmonary fibrosis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Legs poix, Chancellerie des Universit&#x000e9;s de Paris, Sorbonne</funding-source></award-group><award-group id="funding-0002"><funding-source>Bonus Qualite Recherche Universite Sorbonne Paris Nord</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="8"/><word-count count="4400"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PHY270335-cit-2001">
<string-name>
<surname>Maakoul</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Yegen</surname>, <given-names>C.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bernaudin</surname>, <given-names>J.&#x02010;F.</given-names>
</string-name>, <string-name>
<surname>Plan&#x000e8;s</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Voituron</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Boncoeur</surname>, <given-names>E.</given-names>
</string-name> (<year>2025</year>). <article-title>Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice</article-title>. <source>Physiological Reports</source>, <volume>13</volume>, <elocation-id>e70335</elocation-id>. <pub-id pub-id-type="doi">10.14814/phy2.70335</pub-id>
</mixed-citation>
</p><fn-group id="phy270335-ntgp-0001"><fn id="phy270335-note-0001"><p>Emilie Boncoeur and Nicolas Voituron contributed equally.</p></fn></fn-group></notes></front><body id="phy270335-body-0001"><sec id="phy270335-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Idiopathic pulmonary fibrosis (IPF), the archetype of progressive pulmonary fibrosis, affecting mainly men over 50, is characterized by a fatal course of shortness of breath and progressive dyspnoea (Hutchinson et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0011" ref-type="bibr">2015</xref>) in the absence of truly curative medical treatment (Olson et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0020" ref-type="bibr">2018</xref>). Although the specific etiology is still unknown, it is widely accepted that the deterioration of the lung architecture and its stiffening would result from repeated microaggressions of the alveolar epithelium and an abnormal repair process (Glass et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0008" ref-type="bibr">2022</xref>). In addition, many studies have implicated monocyte&#x02010;derived macrophages as a key player in the inflammatory process leading to progressive fibrosis (Kim et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0012" ref-type="bibr">2025</xref>).</p><p>In recent years, researchers have highlighted that comorbidities such as OSA may influence the natural history of IPF (Lancaster et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0015" ref-type="bibr">2009</xref>; Papadogiannis et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0021" ref-type="bibr">2021</xref>). A study of patients with incident IPF (French cohort COFI) showed that 62% of patients had moderate to severe OSA and 40% had severe OSA (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0006" ref-type="bibr">2017</xref>). OSA is characterized by brief and consecutive episodes of hypoxia&#x02010;reoxygenation leading to chronic intermittent hypoxia (CIH) due to upper airway obstruction (Dewan et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0004" ref-type="bibr">2015</xref>). CIH leads to chronic systemic inflammation and has been described to have a significant impact in many pathologies affecting the cardiovascular and nervous systems, metabolism (Gnoni et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0009" ref-type="bibr">2022</xref>; Sanderson et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0022" ref-type="bibr">2021</xref>), and the lung (Koritala et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0014" ref-type="bibr">2024</xref>; Shi et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0024" ref-type="bibr">2020</xref>). In the lung, exposure to CIH promotes local inflammation and oxidative stress (Koritala et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0014" ref-type="bibr">2024</xref>; Zhang et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0029" ref-type="bibr">2018</xref>). Studies in rodent models of bleomycin&#x02010;induced pulmonary fibrosis have shown that CIH increases lung oxidative stress in the lung (Lee et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0017" ref-type="bibr">2023</xref>; Xiong et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0025" ref-type="bibr">2021</xref>), recruitment of pro&#x02010;inflammatory cells and cytokine release (Braun et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0003" ref-type="bibr">2018</xref>; Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>), and exacerbates lung fibrosis and mortality. Furthermore, the detrimental effects of CIH were exacerbated when initiated before the induction of lung fibrosis (Haine et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0010" ref-type="bibr">2021</xref>).</p><p>Continuous positive airway pressure (CPAP) is an effective treatment for OSA when well tolerated and used correctly (Lazzeri et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0016" ref-type="bibr">2024</xref>). To date, the impact of OSA treatment on the course of IPF has never been evaluated using a robust methodology. However, preliminary studies suggest that patients with IPF and OSA who are well compliant with CPAP have a higher quality of life and a longer life expectancy than those who are poorly compliant (Mermigkis et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0019" ref-type="bibr">2015</xref>; Papadogiannis et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0021" ref-type="bibr">2021</xref>). In the present study, we investigated the effect of early cessation of CIH (at the onset of fibrosis) on both fibrosis severity and the lung inflammatory cell infiltration in a mouse model of bleomycin&#x02010;induced pulmonary fibrosis.</p></sec><sec sec-type="materials-and-methods" id="phy270335-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="phy270335-sec-0003"><label>2.1</label><title>Animals</title><p>The experiments were approved by our ethics committee and by the French Ministry of Higher Education, Research, and Innovation (n&#x000b0; #18309), and performed in accordance with the European Community Council Directive 2010/63/EU on the animals care. Ten male C57BL/6JRj mice (Janvier Labs; 8&#x02009;weeks old, weight 24&#x02009;&#x000b1;&#x02009;6&#x02009;g) were used. Mice were housed under standard conditions (12&#x02009;h/12&#x02009;h light/dark cycle; food and water ad&#x000a0;libitum).</p></sec><sec id="phy270335-sec-0004"><label>2.2</label><title>Exposure to chronic intermittent hypoxia and induction of lung fibrosis</title><p>Mice were initially exposed to 21&#x02009;days of CIH (30&#x02009;cycles/h, 8&#x02009;h/day, nadir 7% O<sub>2</sub>) as previously described (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>; Haine et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0010" ref-type="bibr">2021</xref>) (Figure&#x000a0;<xref rid="phy270335-fig-0001" ref-type="fig">1a</xref>). After 21&#x02009;days, pulmonary fibrosis was induced by intra&#x02010;tracheal instillation (ITI) of bleomycin (BLM 525709, Bellon&#x02013;Sanofi, Aventis) at 3.5&#x02009;IU/g in 150&#x02009;&#x003bc;L of PBS under anesthesia (Vetflurane, Virbac). Half of the mice were exposed to CIH for a further 21&#x02009;days (CIH/BLM&#x02010;CIH group, <italic toggle="yes">n</italic>&#x02009;=&#x02009;5), while the other half were exposed to air (CIH/BLM&#x02010;Air group, <italic toggle="yes">n</italic>&#x02009;=&#x02009;5). Body weight and vital signs were monitored daily.</p><fig position="float" fig-type="FIGURE" id="phy270335-fig-0001"><label>FIGURE 1</label><caption><p>Experimental design and body mass evolution. (a) Mice were exposed to chronic intermittent hypoxia (CIH; 30&#x02009;cycles/hour, 8&#x02009;h/day, nadir 7% O<sub>2</sub>) for 21&#x02009;days. Subsequently, they received an intratracheal instillation (IT) of 3.5 UI/g of bleomycin (BLM) and then half of the animals were left in CIH for another 21&#x02009;days (CIH/BLM&#x02010;CIH; <italic toggle="yes">n</italic>&#x02009;=&#x02009;5) whereas the other half were left in air (CIH/BLM&#x02010;Air; <italic toggle="yes">n</italic>&#x02009;=&#x02009;5). (b) Body mass was monitored for all mice and was represented by percentage of mass loss from the day of IT instillation of BLM (median&#x02009;&#x000b1;&#x02009;IR).</p></caption><graphic xlink:href="PHY2-13-e70335-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="phy270335-sec-0005"><label>2.3</label><title>Collection of lung samples</title><p>Mice were deeply anesthetized by intraperitoneal injection of ketamine (Virbac, 100&#x02009;mg/kg)/xylazine (Bayer Healthcare, 20&#x02009;mg/kg), tracheotomized, and euthanized by abdominal aortic section. Lungs were flushed with PBS via the pulmonary artery. The lobes were insufflated and fixed with 4% paraformaldehyde at a constant pressure (20&#x02009;cm H<sub>2</sub>O) through the tracheostomy tube. The lungs were removed, post&#x02010;fixed in 4% paraformaldehyde (24&#x02009;h, 4&#x000b0;C), dehydrated, and paraffin&#x02010;embedded.</p></sec><sec id="phy270335-sec-0006"><label>2.4</label><title>Histological approaches</title><p>Lung sections (5&#x02009;&#x003bc;m) were cleared in xylene, rehydrated, and stained by hematoxylin&#x02010;eosin or Masson's trichrome (Yegen et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0027" ref-type="bibr">2022</xref>). Quantification of affected parenchymal areas and collagen deposition were performed on five microscopic images for each mouse using a Zeiss Axioscope (&#x000d7;400 magnification, &#x000d7;40 objective). Image J/Fiji toolbox was used for analysis (S&#x000e9;gard et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0023" ref-type="bibr">2024</xref>). Tissue remodeling was estimated by the ratio of the injured area to the total area. Masson's trichrome was used to quantify the percentage of collagen coverage (aniline bluestained area) using the ColorDeconvolution2 plugin. Quantification of pulmonary fibrosis was assessed using a modified Ashcroft score as previously described (Ashcroft et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0002" ref-type="bibr">1988</xref>; Yegen et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0028" ref-type="bibr">2023</xref>) according to five stages from normal to a completely remodeled lung (score 1 to 5). The mean linear intercept method using the grid tool in ImageJ software was used on hematoxylin&#x02010;eosin stained sections as a morphometric estimation of alveolar surface destruction, a marker of fibrosis (Xu et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0026" ref-type="bibr">2021</xref>).</p></sec><sec id="phy270335-sec-0007"><label>2.5</label><title>Immunohistochemistry to assess inflammatory cell infiltrates</title><p>Antigen retrieval was performed in a boiling citrate buffer. Endogenous peroxidases were blocked with 3% H<sub>2</sub>O<sub>2</sub>, and sections were incubated with 5% horse serum and primary antibodies (24&#x02009;h, 4&#x000b0;C; Table&#x000a0;<xref rid="phy270335-tbl-0001" ref-type="table">1</xref>). F4&#x02010;80, Ly6G, and CD4 antibodies were used for the identification of macrophages, neutrophils, and T lymphocytes, respectively. An isotopic antibody control was performed. After 24&#x02009;h, the slides were incubated with biotin&#x02010;conjugated secondary antibodies (Dako) and with HRP&#x02010;conjugated streptavidin (Vector Lab). DAB (3,3&#x02032;&#x02010;diaminobenzidine) and nuclear fast red (Sigma Aldrich) staining were used to visualize immunolabeling. Semi&#x02010;quantification was performed by counting positive cells in three images per mouse at &#x000d7;400 magnification (objective lens &#x000d7;40) on Zeiss Axioscope using Histolab image analysis software (V10.1), in an area with large continuous fibrotic masses, with normal architecture without fibrotic burden, and with both architectures.</p><table-wrap position="float" id="phy270335-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>List of antibodies used for immunohistochemistry.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Antibody</th><th align="left" valign="bottom" rowspan="1" colspan="1">References</th><th align="left" valign="bottom" rowspan="1" colspan="1">Dilution</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">F4&#x02010;80</td><td align="left" valign="top" rowspan="1" colspan="1">D2S9R, Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">1:250</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ly6G</td><td align="left" valign="top" rowspan="1" colspan="1">Ab238132, Abcam</td><td align="left" valign="top" rowspan="1" colspan="1">1:500</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD4</td><td align="left" valign="top" rowspan="1" colspan="1">D7D2Z, Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">1:100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isotype</td><td align="left" valign="top" rowspan="1" colspan="1">Rabbit IgG, Control, Vector Lab (I&#x02010;1000)</td><td align="left" valign="top" rowspan="1" colspan="1">1:3300</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Secondary</td><td align="left" valign="top" rowspan="1" colspan="1">Horse Anti&#x02010;Rabbit IgG, Biotinylated, Vector Lab (BA&#x02010;1100)</td><td align="left" valign="top" rowspan="1" colspan="1">1:200</td></tr></tbody></table></table-wrap></sec><sec id="phy270335-sec-0008"><label>2.6</label><title>Statistical analysis</title><p>Graphical and statistical analyses were performed using GraphPad Prism (GraphPad Software, V9). Normality of data distribution was assessed using the Shapiro&#x02013;Wilk normality test. Results were expressed as median&#x02009;&#x000b1;&#x02009;interquartile range (median&#x02009;&#x000b1;&#x02009;IR). Comparisons between groups were assessed using the Mann&#x02013;Whitney test, and differences were considered significant when <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="results" id="phy270335-sec-0009"><label>3</label><title>RESULTS</title><p>During the first 21&#x02009;days of CIH exposure, prior to the BLM&#x02010;ITI, the body mass of the mice was not altered (not shown). After induction of lung fibrosis, the mice lost weight without a significant difference between the two groups (13%&#x02013;15% decrease observed at D21 in CIH/BLM&#x02010;Air group compared to the CIH/BLM&#x02010;CIH group) (Figure&#x000a0;<xref rid="phy270335-fig-0001" ref-type="fig">1b</xref>).</p><p>The CIH/BLM&#x02010;CIH group showed changes in the lung architecture (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2a,b</xref>), with subpleural and diffuse lesions. Interestingly, the cessation of CIH after BLM&#x02010;ITI (CIH/BLM&#x02010;Air group) resulted in less significant lung damage compared to the group maintained in CIH exposure (CIH/BLM&#x02010;CIH). A significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) 32% reduction in the fibrotic lesions area was observed (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2b,d</xref>). Masson's trichrome analysis showed less collagen deposition in the CIH/BLM&#x02010;Air group as compared to CIH/BLM&#x02010;CIH (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2c</xref>), which was confirmed by quantification (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2f</xref>). A lower linear intercept indicated less alveolar destruction associated with fibrosis (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2e</xref>). The fibrosis score was lower in the CIH/BLM&#x02010;Air group with less extensive lesions, mainly in the subpleural area compared to CIH/BLM&#x02010;CIH. Furthermore, we also quantified a lower mean lesion severity score from 3.4&#x02009;&#x000b1;&#x02009;1.1 (out of 5) in the CIH/BLM&#x02010;CIH group to 1.7&#x02009;&#x000b1;&#x02009;0.74 (out of 5) in the CIH/BLM&#x02010;Air group (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2g</xref>). In addition, the CIH/BLM&#x02010;Air group had fewer areas with severe scores (grades 4 and 5) and the presence of grade 2. In comparison, the CIH/BLM&#x02010;CIH group showed only lesions with scores ranging from 3 to 5. Interestingly, despite the reduction in fibrosis score, no area without fibrotic burden has been observed (score of 1) in either group (Figure&#x000a0;<xref rid="phy270335-fig-0002" ref-type="fig">2g</xref>).</p><fig position="float" fig-type="FIGURE" id="phy270335-fig-0002"><label>FIGURE 2</label><caption><p>Pulmonary architecture. (a) Cartography of mouse lungs stained with Hematoxylin Eosin. (b) Illustration of injured area (&#x000d7;40 magnification). (c) Histologic illustration of collagen deposition (Masson's Trichrome staining, x40 magnification). (a, b, and c) A representative image of mice lung from the CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) groups was shown. (d) Quantification of lung injury area reported to the total lung surface, (e) Mean Linear Intercept (MLI) measured on five microscopic images obtained at &#x000d7;40 magnification of Hematoxylin Eosin&#x02010;stained lung biopsy sections, (f) Percentage of collagen occupation on lungs stained with Masson's trichrome of all the mice from the CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) groups. (g) Histogram bars represent the mean of Aschroft scores with the intra proportion of different fibrotic stages from 1 (normal lung, no fibrotic burden and small fibers) to 5 (completely remodeled lung, large continuous fibrotic masses &#x0003e;50%). Scoring was performed on five images each from CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) mice.</p></caption><graphic xlink:href="PHY2-13-e70335-g003" position="anchor" id="jats-graphic-3"/></fig><p>Regarding lung inflammation, the CIH/BLM&#x02010;Air group showed fewer inflammatory cells (Figure&#x000a0;<xref rid="phy270335-fig-0003" ref-type="fig">3</xref>), due to a 50% reduction in the number of macrophages (F480) (Figure&#x000a0;<xref rid="phy270335-fig-0003" ref-type="fig">3a,d</xref>) as compared to the CIH/BLM&#x02010;CIH group (302.2&#x02009;&#x000b1;&#x02009;86.7 vs. 561.2&#x02009;&#x000b1;&#x02009;143.9 cells respectively, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). In contrast, there was no difference in the number of T lymphocytes (CD4) and neutrophils (Ly6G) (Figure&#x000a0;<xref rid="phy270335-fig-0003" ref-type="fig">3b,c</xref>). This led to a change in the proportion of each cell type (Figure&#x000a0;<xref rid="phy270335-fig-0003" ref-type="fig">3e</xref>). F4&#x02010;80 positive cells, which represented 70% of the total population analyzed in the CIH/BLM&#x02010;CIH group, represented only 60% in the CIH/BLM&#x02010;Air group. The proportions of CD4 and Ly6G&#x02010;positive cells increased by approximately 5% (from 15% to 21% and from 15% to 19%, respectively) (Figure&#x000a0;<xref rid="phy270335-fig-0003" ref-type="fig">3e</xref>).</p><fig position="float" fig-type="FIGURE" id="phy270335-fig-0003"><label>FIGURE 3</label><caption><p>Pulmonary inflammatory response. (a, b, and c) Analysis of differential inflammatory cells by immunohistochemistry for total F4&#x02010;80 (a), Ly6G (b), and CD4 positive cells (c) performed on 5&#x02009;&#x003bc;m lung biopsy sections. A representative image of mice from the CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) groups is shown. (d) Semi&#x02010;quantification of F4&#x02010;80, Ly6G, and CD4 positive cells counted in lung sections from CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) mice. (e) Proportions of macrophages (F4&#x02010;80), lymphocytes (CD4), and neutrophils (Ly6G) in the CIH/BLM&#x02010;CIH (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) and CIH/BLM&#x02010;Air (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) groups.</p></caption><graphic xlink:href="PHY2-13-e70335-g002" position="anchor" id="jats-graphic-5"/></fig></sec><sec sec-type="discussion" id="phy270335-sec-0010"><label>4</label><title>DISCUSSION</title><p>We have previously shown that CIH exacerbates BLM&#x02010;induced pulmonary fibrosis in mice (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>) and that this worsening effect was strengthened when CIH was initiated before the induction of lung fibrosis and continued thereafter (Haine et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0010" ref-type="bibr">2021</xref>). Here, we propose to document the severity and evolution of lung fibrosis when CIH is interrupted at the onset of lung fibrosis. Our results showed that this interruption with reintroduction of air breathing significantly reduced the severity of lung injury and inflammatory status.</p><p>Exposure to CIH at the onset of fibrosis induction in the BLM&#x02010;mouse model has previously been shown to induce a higher mortality, associated with a more severe fibrosis as assessed by lung collagen content and histological characterization (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>; Haine et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0010" ref-type="bibr">2021</xref>). In addition, neutrophilic alveolitis and increased oxidative/nitrosative stress were observed in the first week after BLM instillation in the lungs of mice exposed to CIH, followed by pulmonary oedema and increased lung cell apoptosis (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>). Furthermore, when CIH was applied 2&#x02009;weeks before the onset of fibrosis, induction of pro&#x02010;fibrotic markers, increased tissue injury, and collagen deposition were observed (Haine et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0010" ref-type="bibr">2021</xref>). This demonstrates the detrimental effect of CIH exposure on the induction and severity of fibrosis whether it is applied before or at the same time as BLM instillation. Our study showed deep lung remodeling in the CIH/BLM&#x02010;CIH group with reduced mean air space area, increased collagen deposition, and a notable proportion of high Ashcroft scores (more than 50% of slides at level 5). Finally, we showed a high proportion of macrophage population in the lung (70%), within the range of values classically found in the literature (Kim et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0013" ref-type="bibr">2010</xref>).</p><p>When CIH was stopped at the onset of pulmonary fibrosis induction (i.e., at the time of BLM instillation), we observed an overall less severe form of lung fibrosis, less diffuse lung fibrosis with a reduced ratio of damaged area, reduced collagen deposition and fibrosis score, and a larger air&#x02010;filled area. Several hypotheses can be put forward to explain these observations. The first hypothesis which was also the subject of this study is a global change in the inflammatory state as a consequence of the interruption of CIH. Indeed, we have shown that cessation of CIH specifically reduces the number of macrophages in the affected areas, while other inflammatory cells remain unchanged. Given the critical role of macrophage accumulation in lung fibrogenesis (Fabre et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0005" ref-type="bibr">2023</xref>) and the link between lung macrophage dynamics and inflammation/fibrosis (Aisanjiang et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0001" ref-type="bibr">2024</xref>), a reduction in pro&#x02010;inflammatory macrophages may lead to a less severe form of fibrosis. This explanation is consistent with the observation that patients treated with CPAP have reduced the inflammatory cytokine release (Mahboub et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0018" ref-type="bibr">2022</xref>). However, to our knowledge, the effect of CPAP treatment on the lung inflammatory status of IPF patients with OSA has never been documented.</p><p>The reduction in lung lesion severity observed after cessation of CIH may be due to a reduction in M2&#x02010;polarized macrophages and released pro&#x02010;fibrosing factors (Braun et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0003" ref-type="bibr">2018</xref>; Kim et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0012" ref-type="bibr">2025</xref>), as a consequence of the overall reduction in the macrophage population. It would be interesting to evaluate the modulation of these specific molecular markers secreted by macrophages (i.e, TGF&#x003b2;, IL13, or VEGF) with and without the interruption of CIH in the broncho&#x02010;alveolar lavage of mice or the activation of downstream signaling pathways within the lung tissue. An alternative explanation would be a reduction in oxidative stress and reactive oxygen species, which could limit epithelial cell injury and apoptosis (Gille et&#x000a0;al.,&#x000a0;<xref rid="phy270335-bib-0007" ref-type="bibr">2018</xref>). This hypothesis remains to be explored. Finally, the beneficial impact of cessation of CIH on the severity of lung fibrosis at the indicated time point could also be due to the repair process activation. This point and the signaling pathways involved should be further investigated.</p><p>In conclusion, this study highlights the beneficial effect of cessation of CIH on the severity of the ongoing fibrosis and provides a proof of concept that early treatment of OSA&#x02010;associated CIH limits the development of severe progressive forms of lung fibrosis.</p></sec><sec id="phy270335-sec-0011"><title>AUTHOR CONTRIBUTIONS</title><p>NV and EB designed the experiments. ZM, C&#x02010;HY, DM, JF&#x02010;B, NV, and EB performed and analyzed the experiments. NV and EB wrote the manuscript. ZM, C&#x02010;HY, DM, JF&#x02010;B, CP, NV, and EB discussed the data and revised the manuscript. All authors approved the submitted version.</p></sec><sec id="phy270335-sec-0013"><title>FUNDING INFORMATION</title><p>&#x0201c;Institut F&#x000e9;d&#x000e9;ratif de Recherche Biom&#x000e9;dicale&#x0201d; programs of the USPN (NV&#x02010;2020) and &#x0201c;Legs Poix&#x0201d; grant (NV&#x02010;2018).</p></sec><sec sec-type="COI-statement" id="phy270335-sec-0014"><title>CONFLICT OF INTEREST STATEMENT</title><p>No conflicts of interest.</p></sec><sec id="phy270335-sec-0114"><title>ETHICS STATEMENT</title><p>The experiments were approved by our ethics committee and by the French Ministry of Higher Education, Research, and Innovation (n&#x000b0; #18309), and performed in accordance with the European Community Council Directive 2010/63/EU on the animals care.</p></sec></body><back><ack id="phy270335-sec-0012"><title>ACKNOWLEDGMENTS</title><p>The authors thank the Animal Facility staff for their assistance, and O. Jones and E. Tubbs for editing the manuscript.</p></ack><sec sec-type="data-availability" id="phy270335-sec-0016"><title>DATA AVAILABILITY STATEMENT</title><p>Data will be made available on request.</p></sec><ref-list content-type="cited-references" id="phy270335-bibl-0001"><title>REFERENCES</title><ref id="phy270335-bib-0001"><mixed-citation publication-type="journal" id="phy270335-cit-0001">
<string-name>
<surname>Aisanjiang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dai</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liao</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Tong</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lu</surname>, <given-names>Y.</given-names>
</string-name> (<year>2024</year>). <article-title>Ameliorating lung fibrosis and pulmonary function in diabetic mice: Therapeutic potential of mesenchymal stem cell</article-title>. <source>Biochemical and Biophysical Research Communications</source>, <volume>737</volume>, <elocation-id>150495</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2024.150495</pub-id>
<pub-id pub-id-type="pmid">39126861</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0002"><mixed-citation publication-type="journal" id="phy270335-cit-0002">
<string-name>
<surname>Ashcroft</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>, <given-names>J. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Timbrell</surname>, <given-names>V.</given-names>
</string-name> (<year>1988</year>). <article-title>Simple method of estimating severity of pulmonary fibrosis on a numerical scale</article-title>. <source>Journal of Clinical Pathology</source>, <volume>41</volume>, <fpage>467</fpage>&#x02013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.41.4.467</pub-id>
<pub-id pub-id-type="pmid">3366935</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0003"><mixed-citation publication-type="journal" id="phy270335-cit-0003">
<string-name>
<surname>Braun</surname>, <given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Broytman</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Braun</surname>, <given-names>F. M.</given-names>
</string-name>, <string-name>
<surname>Brinkman</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Clithero</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Modi</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pegelow</surname>, <given-names>D. F.</given-names>
</string-name>, <string-name>
<surname>Eldridge</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Teodorescu</surname>, <given-names>M.</given-names>
</string-name> (<year>2018</year>). <article-title>Chronic intermittent hypoxia worsens bleomycin&#x02010;induced lung fibrosis in rats</article-title>. <source>Respiratory Physiology &#x00026; Neurobiology</source>, <volume>256</volume>, <fpage>97</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.resp.2017.04.010</pub-id>
<pub-id pub-id-type="pmid">28456608</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0004"><mixed-citation publication-type="journal" id="phy270335-cit-0004">
<string-name>
<surname>Dewan</surname>, <given-names>N. A.</given-names>
</string-name>, <string-name>
<surname>Nieto</surname>, <given-names>F. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Somers</surname>, <given-names>V. K.</given-names>
</string-name> (<year>2015</year>). <article-title>Intermittent hypoxemia and OSA: Implications for comorbidities</article-title>. <source>Chest</source>, <volume>147</volume>, <fpage>266</fpage>&#x02013;<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1378/chest.14-0500</pub-id>
<pub-id pub-id-type="pmid">25560865</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0005"><mixed-citation publication-type="journal" id="phy270335-cit-0005">
<string-name>
<surname>Fabre</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Barron</surname>, <given-names>A. M. S.</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Asano</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bound</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Lech</surname>, <given-names>M. P.</given-names>
</string-name>, <string-name>
<surname>Wadsworth</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schlerman</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>White</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kravarik</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Borthwick</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Hart</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>, <given-names>N. C.</given-names>
</string-name>, <string-name>
<surname>Wynn</surname>, <given-names>T. A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Dower</surname>, <given-names>K.</given-names>
</string-name> (<year>2023</year>). <article-title>Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation</article-title>. <source>Science Immunology</source>, <volume>8</volume>, <elocation-id>eadd8945</elocation-id>. <pub-id pub-id-type="doi">10.1126/sciimmunol.add8945</pub-id>
<pub-id pub-id-type="pmid">37027478</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0006"><mixed-citation publication-type="journal" id="phy270335-cit-0006">
<string-name>
<surname>Gille</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Didier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Boubaya</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Moya</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Carton</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Baran&#x02010;Marszak</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Sadoun&#x02010;Danino</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Isra&#x000eb;l&#x02010;Biet</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Cottin</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Gagnadoux</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Crestani</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>d'Ortho</surname>, <given-names>M.&#x02010;P.</given-names>
</string-name>, <string-name>
<surname>Brillet</surname>, <given-names>P.&#x02010;Y.</given-names>
</string-name>, <string-name>
<surname>Valeyre</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Nunes</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Plan&#x000e8;s</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <collab collab-type="authors">Collaborators</collab>
. (<year>2017</year>). <article-title>Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis</article-title>. <source>The European Respiratory Journal</source>, <volume>49</volume>, <elocation-id>1601934</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.01934-2016</pub-id>
<pub-id pub-id-type="pmid">28596432</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0007"><mixed-citation publication-type="journal" id="phy270335-cit-0007">
<string-name>
<surname>Gille</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Didier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rotenberg</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Delbrel</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sutton</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dard</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Haine</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Voituron</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Bernaudin</surname>, <given-names>J.&#x02010;F.</given-names>
</string-name>, <string-name>
<surname>Valeyre</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Nunes</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Besnard</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Boncoeur</surname>, <given-names>E.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Plan&#x000e8;s</surname>, <given-names>C.</given-names>
</string-name> (<year>2018</year>). <article-title>Intermittent hypoxia increases the severity of bleomycin&#x02010;induced lung injury in mice</article-title>. <source>Oxidative Medicine and Cellular Longevity</source>, <volume>2018</volume>, <elocation-id>1240192</elocation-id>. <pub-id pub-id-type="doi">10.1155/2018/1240192</pub-id>
<pub-id pub-id-type="pmid">29725493</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0008"><mixed-citation publication-type="journal" id="phy270335-cit-0008">
<string-name>
<surname>Glass</surname>, <given-names>D. S.</given-names>
</string-name>, <string-name>
<surname>Grossfeld</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Renna</surname>, <given-names>H. A.</given-names>
</string-name>, <string-name>
<surname>Agarwala</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Spiegler</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>DeLeon</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Reiss</surname>, <given-names>A. B.</given-names>
</string-name> (<year>2022</year>). <article-title>Idiopathic pulmonary fibrosis: Current and future treatment</article-title>. <source>The Clinical Respiratory Journal</source>, <volume>16</volume>, <fpage>84</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1111/crj.13466</pub-id>
<pub-id pub-id-type="pmid">35001525</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0009"><mixed-citation publication-type="journal" id="phy270335-cit-0009">
<string-name>
<surname>Gnoni</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Ilic</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Drakatos</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Petrinovic</surname>, <given-names>M. M.</given-names>
</string-name>, <string-name>
<surname>Cash</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Steier</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Morrell</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Petanjek</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Kalanj&#x02010;Bognar</surname>, <given-names>S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Rosenzweig</surname>, <given-names>I.</given-names>
</string-name> (<year>2022</year>). <article-title>Obstructive sleep apnea and multiple facets of a neuroinflammatory response: A narrative review</article-title>. <source>Journal of Thoracic Disease</source>, <volume>14</volume>, <fpage>564</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.21037/jtd-21-1231</pub-id>
<pub-id pub-id-type="pmid">35280483</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0010"><mixed-citation publication-type="journal" id="phy270335-cit-0010">
<string-name>
<surname>Haine</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Bravais</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yegen</surname>, <given-names>C.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Bernaudin</surname>, <given-names>J.&#x02010;F.</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Plan&#x000e8;s</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Voituron</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Boncoeur</surname>, <given-names>E.</given-names>
</string-name> (<year>2021</year>). <article-title>Sleep apnea in idiopathic pulmonary fibrosis: A molecular investigation in an experimental model of fibrosis and intermittent hypoxia</article-title>. <source>Life (Basel, Switzerland)</source>, <volume>11</volume>, <elocation-id>973</elocation-id>. <pub-id pub-id-type="doi">10.3390/life11090973</pub-id>
<pub-id pub-id-type="pmid">34575121</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0011"><mixed-citation publication-type="journal" id="phy270335-cit-0011">
<string-name>
<surname>Hutchinson</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fogarty</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hubbard</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>McKeever</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review</article-title>. <source>The European Respiratory Journal</source>, <volume>46</volume>, <fpage>795</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00185114</pub-id>
<pub-id pub-id-type="pmid">25976683</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0012"><mixed-citation publication-type="journal" id="phy270335-cit-0012">
<string-name>
<surname>Kim</surname>, <given-names>D. H.</given-names>
</string-name>, <string-name>
<surname>Im</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Baek</surname>, <given-names>I.&#x02010;J.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>, <given-names>Y. J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>D.&#x02010;S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>C. W.</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ban</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>S.&#x02010;Y.</given-names>
</string-name>, <string-name>
<surname>Ji</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>H.&#x02010;Y.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yun</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>H. C.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>, <given-names>C. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Rho</surname>, <given-names>J. K.</given-names>
</string-name> (<year>2025</year>). <article-title>Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarization</article-title>. <source>European Respiratory Journal</source>, <volume>9</volume>, <elocation-id>2400615</elocation-id>.</mixed-citation></ref><ref id="phy270335-bib-0013"><mixed-citation publication-type="journal" id="phy270335-cit-0013">
<string-name>
<surname>Kim</surname>, <given-names>S. N.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>H.&#x02010;S.</given-names>
</string-name>, <string-name>
<surname>Cho</surname>, <given-names>J.&#x02010;W.</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>Y.&#x02010;B.</given-names>
</string-name>, <string-name>
<surname>Her</surname>, <given-names>J.&#x02010;D.</given-names>
</string-name>, <string-name>
<surname>Cho</surname>, <given-names>K.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>C.&#x02010;W.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lee</surname>, <given-names>K.</given-names>
</string-name> (<year>2010</year>). <article-title>Dose&#x02010;response effects of bleomycin on inflammation and pulmonary fibrosis in mice</article-title>. <source>Toxicology Research</source>, <volume>26</volume>, <fpage>217</fpage>&#x02013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.5487/TR.2010.26.3.217</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0014"><mixed-citation publication-type="journal" id="phy270335-cit-0014">
<string-name>
<surname>Koritala</surname>, <given-names>B. S. C.</given-names>
</string-name>, <string-name>
<surname>Gaspar</surname>, <given-names>L. S.</given-names>
</string-name>, <string-name>
<surname>Bhadri</surname>, <given-names>S. S.</given-names>
</string-name>, <string-name>
<surname>Massie</surname>, <given-names>K. S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>Y. Y.</given-names>
</string-name>, <string-name>
<surname>Paulose</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Smith</surname>, <given-names>D. F.</given-names>
</string-name> (<year>2024</year>). <article-title>Murine pro&#x02010;inflammatory responses to acute and sustained intermittent hypoxia: Implications for obstructive sleep apnea research</article-title>. <source>The Laryngoscope</source>, <volume>134</volume>(<issue>Suppl 4</issue>), <fpage>S1</fpage>&#x02013;<lpage>S11</lpage>. <pub-id pub-id-type="doi">10.1002/lary.30915</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0015"><mixed-citation publication-type="journal" id="phy270335-cit-0015">
<string-name>
<surname>Lancaster</surname>, <given-names>L. H.</given-names>
</string-name>, <string-name>
<surname>Mason</surname>, <given-names>W. R.</given-names>
</string-name>, <string-name>
<surname>Parnell</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Rice</surname>, <given-names>T. W.</given-names>
</string-name>, <string-name>
<surname>Loyd</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Milstone</surname>, <given-names>A. P.</given-names>
</string-name>, <string-name>
<surname>Collard</surname>, <given-names>H. R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Malow</surname>, <given-names>B. A.</given-names>
</string-name> (<year>2009</year>). <article-title>Obstructive sleep apnea is common in idiopathic pulmonary fibrosis</article-title>. <source>Chest</source>, <volume>136</volume>, <fpage>772</fpage>&#x02013;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1378/chest.08-2776</pub-id>
<pub-id pub-id-type="pmid">19567497</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0016"><mixed-citation publication-type="journal" id="phy270335-cit-0016">
<string-name>
<surname>Lazzeri</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Houot</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Patout</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Londner</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Philippe</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Attard</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Delpy</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ruggeri</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Degos</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Cormier</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Vidailhet</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Corvol</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Arnulf</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Grabli</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Dodet</surname>, <given-names>P.</given-names>
</string-name> (<year>2024</year>). <article-title>Immediate effect of continuous positive airway pressure therapy on sleep and respiration in patients with multiple system atrophy and sleep&#x02010;disordered breathing</article-title>. <source>Movement Disorders</source>, <volume>39</volume>, <fpage>2026</fpage>&#x02013;<lpage>2038</lpage>. <pub-id pub-id-type="doi">10.1002/mds.29993</pub-id>
<pub-id pub-id-type="pmid">39285740</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0017"><mixed-citation publication-type="journal" id="phy270335-cit-0017">
<string-name>
<surname>Lee</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>I. K.</given-names>
</string-name>, <string-name>
<surname>Im</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Jin</surname>, <given-names>B. S.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>H. H.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>S. W.</given-names>
</string-name>, <string-name>
<surname>Yeo</surname>, <given-names>C. D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lee</surname>, <given-names>S. H.</given-names>
</string-name> (<year>2023</year>). <article-title>Effects of aging on accompanying intermittent hypoxia in a bleomycin&#x02010;induced pulmonary fibrosis mouse model</article-title>. <source>The Korean Journal of Internal Medicine</source>, <volume>38</volume>, <fpage>934</fpage>&#x02013;<lpage>944</lpage>. <pub-id pub-id-type="doi">10.3904/kjim.2023.090</pub-id>
<pub-id pub-id-type="pmid">37793985</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0018"><mixed-citation publication-type="journal" id="phy270335-cit-0018">
<string-name>
<surname>Mahboub</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Kharaba</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Ramakrishnan</surname>, <given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Sharif Askari</surname>, <given-names>N. S.</given-names>
</string-name>, <string-name>
<surname>Salameh</surname>, <given-names>L. I.</given-names>
</string-name>, <string-name>
<surname>Alhariri</surname>, <given-names>H. S.</given-names>
</string-name>, <string-name>
<surname>Vats</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Erabia</surname>, <given-names>W. T.</given-names>
</string-name>, <string-name>
<surname>Alshawamreh</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Alfoteih</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Mogas</surname>, <given-names>A. K.</given-names>
</string-name>, <string-name>
<surname>Halwani</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Hamid</surname>, <given-names>Q.</given-names>
</string-name> (<year>2022</year>). <article-title>Continuous positive airway pressure therapy suppresses inflammatory cytokines and improves glucocorticoid responsiveness in patients with obstructive sleep apnea and asthma: A case&#x02013;control study</article-title>. <source>Annals of Thoracic Medicine</source>, <volume>17</volume>, <fpage>166</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.4103/atm.atm_37_22</pub-id>
<pub-id pub-id-type="pmid">35968397</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0019"><mixed-citation publication-type="journal" id="phy270335-cit-0019">
<string-name>
<surname>Mermigkis</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bouloukaki</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Antoniou</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Papadogiannis</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Giannarakis</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Varouchakis</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Siafakas</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Schiza</surname>, <given-names>S. E.</given-names>
</string-name> (<year>2015</year>). <article-title>Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis</article-title>. <source>Sleep Breath Schlaf Atm</source>, <volume>19</volume>, <fpage>385</fpage>&#x02013;<lpage>391</lpage>. <pub-id pub-id-type="doi">10.1007/s11325-014-1033-6</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0020"><mixed-citation publication-type="journal" id="phy270335-cit-0020">
<string-name>
<surname>Olson</surname>, <given-names>A. L.</given-names>
</string-name>, <string-name>
<surname>Gifford</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Inase</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez P&#x000e9;rez</surname>, <given-names>E. R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Suda</surname>, <given-names>T.</given-names>
</string-name> (<year>2018</year>). <article-title>The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive&#x02010;fibrosing phenotype</article-title>. <source>European Respiratory Review</source>, <volume>27</volume>, <elocation-id>180077</elocation-id>. <pub-id pub-id-type="doi">10.1183/16000617.0077-2018</pub-id>
<pub-id pub-id-type="pmid">30578336</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0021"><mixed-citation publication-type="journal" id="phy270335-cit-0021">
<string-name>
<surname>Papadogiannis</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Bouloukaki</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mermigkis</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Michelakis</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ermidou</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Mauroudi</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Moniaki</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Tzanakis</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Antoniou</surname>, <given-names>K. M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Schiza</surname>, <given-names>S. E.</given-names>
</string-name> (<year>2021</year>). <article-title>Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: Differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment</article-title>. <source>Journal of Clinical Sleep Medicine</source>, <volume>17</volume>, <fpage>533</fpage>&#x02013;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.5664/jcsm.8932</pub-id>
<pub-id pub-id-type="pmid">33108270</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0022"><mixed-citation publication-type="journal" id="phy270335-cit-0022">
<string-name>
<surname>Sanderson</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Fang</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>C. Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Wei</surname>, <given-names>Y. X.</given-names>
</string-name> (<year>2021</year>). <article-title>Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction</article-title>. <source>Heart: An Open Access Journal of the British Cardiovascular Society</source>, <volume>107</volume>, <fpage>190</fpage>&#x02013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2020-317326</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0023"><mixed-citation publication-type="journal" id="phy270335-cit-0023">
<string-name>
<surname>S&#x000e9;gard</surname>, <given-names>B.&#x02010;D.</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Matsuoka</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Imamura</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Iwamiya</surname>, <given-names>T.</given-names>
</string-name> (<year>2024</year>). <article-title>Quantification of fibrosis extend and airspace availability in lung: A semi&#x02010;automatic ImageJ/Fiji toolbox</article-title>. <source>PLoS One</source>, <volume>19</volume>, <elocation-id>e0298015</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0298015</pub-id>
<pub-id pub-id-type="pmid">38421996</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0024"><mixed-citation publication-type="journal" id="phy270335-cit-0024">
<string-name>
<surname>Shi</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Xie</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ouyang</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ke</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Yung</surname>, <given-names>W.&#x02010;H.</given-names>
</string-name> (<year>2020</year>). <article-title>Attenuation of intermittent hypoxia&#x02010;induced apoptosis and fibrosis in pulmonary tissues via suppression of ER stress activation</article-title>. <source>BMC Pulmonary Medicine</source>, <volume>20</volume>, <fpage>92</fpage>. <pub-id pub-id-type="doi">10.1186/s12890-020-1123-0</pub-id>
<pub-id pub-id-type="pmid">32299413</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0025"><mixed-citation publication-type="journal" id="phy270335-cit-0025">
<string-name>
<surname>Xiong</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Mo</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yue</surname>, <given-names>F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Hu</surname>, <given-names>K.</given-names>
</string-name> (<year>2021</year>). <article-title>Intermittent hypoxia increases ROS/HIF&#x02010;1&#x003b1; &#x02018;related oxidative stress and inflammation and worsens bleomycin&#x02010;induced pulmonary fibrosis in adult male C57BL/6J mice</article-title>. <source>International Immunopharmacology</source>, <volume>100</volume>, <elocation-id>108165</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.intimp.2021.108165</pub-id>
<pub-id pub-id-type="pmid">34560512</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0026"><mixed-citation publication-type="journal" id="phy270335-cit-0026">
<string-name>
<surname>Xu</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Vasilescu</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>McDonough</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Coxson</surname>, <given-names>H. O.</given-names>
</string-name>, <string-name>
<surname>Ikezoe</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kinose</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ng</surname>, <given-names>K. W.</given-names>
</string-name>, <string-name>
<surname>Verleden</surname>, <given-names>S. E.</given-names>
</string-name>, <string-name>
<surname>Wuyts</surname>, <given-names>W. A.</given-names>
</string-name>, <string-name>
<surname>Vanaudenaerde</surname>, <given-names>B. M.</given-names>
</string-name>, <string-name>
<surname>Verschakelen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Lenburg</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Morshead</surname>, <given-names>K. B.</given-names>
</string-name>, <string-name>
<surname>Abbas</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<surname>Arron</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Spira</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hackett</surname>, <given-names>T.&#x02010;L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Hogg</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2021</year>). <article-title>The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)</article-title>. <source>eBioMedicine</source>, <volume>66</volume>, <elocation-id>103325</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103325</pub-id>
<pub-id pub-id-type="pmid">33862585</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0027"><mixed-citation publication-type="journal" id="phy270335-cit-0027">
<string-name>
<surname>Yegen</surname>, <given-names>C.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Haine</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Da Costa Ferreira</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bernaudin</surname>, <given-names>J.&#x02010;F.</given-names>
</string-name>, <string-name>
<surname>Plan&#x000e8;s</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Voituron</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Boncoeur</surname>, <given-names>E.</given-names>
</string-name> (<year>2022</year>). <article-title>A new model of acute exacerbation of experimental pulmonary fibrosis in mice</article-title>. <source>Cells</source>, <volume>11</volume>(<issue>21</issue>), <elocation-id>3379</elocation-id>. <pub-id pub-id-type="doi">10.3390/cells11213379</pub-id>
<pub-id pub-id-type="pmid">36359778</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0028"><mixed-citation publication-type="journal" id="phy270335-cit-0028">
<string-name>
<surname>Yegen</surname>, <given-names>C.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bernaudin</surname>, <given-names>J.&#x02010;F.</given-names>
</string-name>, <string-name>
<surname>Planes</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Boncoeur</surname>, <given-names>E.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Voituron</surname>, <given-names>N.</given-names>
</string-name> (<year>2023</year>). <article-title>Chronic pulmonary fibrosis alters the functioning of the respiratory neural network</article-title>. <source>Frontiers in Physiology</source>, <volume>14</volume>, <elocation-id>1205924</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphys.2023.1205924</pub-id>
<pub-id pub-id-type="pmid">37383147</pub-id>
</mixed-citation></ref><ref id="phy270335-bib-0029"><mixed-citation publication-type="journal" id="phy270335-cit-0029">
<string-name>
<surname>Zhang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Rui</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lian</surname>, <given-names>H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Cai</surname>, <given-names>L.</given-names>
</string-name> (<year>2018</year>). <article-title>Sinomenine attenuates chronic intermittent hypoxia&#x02010;induced lung injury by inhibiting inflammation and oxidative stress</article-title>. <source>Medical Science Monitor: International Medical Journal of Experimental and Clinical Research</source>, <volume>24</volume>, <fpage>1574</fpage>&#x02013;<lpage>1580</lpage>. <pub-id pub-id-type="doi">10.12659/msm.906577</pub-id>
<pub-id pub-id-type="pmid">29549235</pub-id>
</mixed-citation></ref></ref-list></back></article>